Kratom, a Southeast Asian plant that acts on opioid receptors, has become a billion-dollar industry in the United States while drawing conflicting responses from health officials and regulators. Families of four deceased men told "60 Minutes" their sons used the substance for energy or to manage other addictions before their deaths. While the American Kratom Association (AKA) describes the plant as a safe herbal supplement, the Food and Drug Administration (FDA) warns against its use due to risks of liver toxicity, seizures, and addiction.
The plant's leaves have been used for generations in Southeast Asia as a stimulant or tea. In the U.S., it is sold in tens of thousands of locations, including gas stations and online retailers. According to the Centers for Disease Control and Prevention (CDC), kratom was detected in more than 5,000 overdose deaths between 2020 and 2024. Justin Brower, a toxicologist at NMS Labs, stated that fatalities linked to the substance have increased approximately tenfold since 2014, with dozens of cases attributed solely to kratom.
Federal regulatory policy has recently shifted regarding 7-OH, a concentrated synthetic substance related to kratom. In July, the federal government announced it would restrict 7-OH and three related substances. However, the Department of Health and Human Services (HHS) changed its recommendation the following month, proposing a 20-fold increase in the allowable amount of 7-OH in products. HHS stated that neither political pressure nor contributions influenced this change, while Dr. Andrew Kolodny of Brandeis University compared the industry's lobbying tactics to those previously used by the manufacturer of OxyContin.
The American Kratom Association, which lobbies the White House and Congress, maintains a distinction between natural kratom and "chemically manipulated products." Public filings indicate millions of dollars have been spent on lobbying and political contributions. Supporters in the government have helped ensure it remains legally available in most states, even as health experts like Kolodny argue its effects are similar to oxycodone and heroin.
This regulatory shift affects consumers who purchase kratom products in retail stores and gas stations across the United States. While the exact number of active users was not reported, the industry has grown into a billion-dollar market. For individuals using kratom to manage opioid addiction or for energy, the increased allowance of 7-OH—a 20-fold rise from previous federal recommendations—changes the potency of products available. The FDA continues to advise against all kratom use, citing risks of substance use disorder and organ damage.
The policy change has implications for federal oversight and state-level legality. Currently, kratom remains legal in most states, but the conflicting messages between the FDA’s warnings and the HHS’s new, higher limits for synthetic components create a complex environment for small-business owners and distributors. For families and health advocates, the concern centers on the potential for increased addiction and fatalities, given that the CDC already linked the substance to 5,000 deaths over a four-year period.
What happens next involves the implementation of these new HHS recommendations and continued monitoring by forensic labs. Toxicologists like Justin Brower continue to track the rising death toll, which he reported has increased tenfold over the last decade. While HHS has declined interviews, their revised stance on 7-OH levels is the current recommendation for federal policy. Future legislative actions or potential FDA interventions will depend on further studies of kratom's health impacts and the ongoing lobbying efforts.